Product Images Fulvestrant

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 18 images provide visual information about the product associated with Fulvestrant NDC 55150-394 by Eugia Us Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fulvestrant figure1 - fulvestrant fig1

fulvestrant figure1 - fulvestrant fig1

fulvestrant figure10 - fulvestrant fig10

fulvestrant figure10 - fulvestrant fig10

fulvestrant figure11 - fulvestrant fig11

fulvestrant figure11 - fulvestrant fig11

fulvestrant-fig12.jpg - fulvestrant fig12

fulvestrant-fig12.jpg - fulvestrant fig12

fulvestrant-fig13.jpg - fulvestrant fig13

fulvestrant-fig13.jpg - fulvestrant fig13

fulvestrant-fig14 - fulvestrant fig14

fulvestrant-fig14 - fulvestrant fig14

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 250 mg per 5 mL (50 mg/mL) Syringe Label - fulvestrant fig15

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 250 mg per 5 mL (50 mg/mL) Syringe Label - fulvestrant fig15

This is a description of a medication called Fulvestrant. It is an injection available in a prefilled syringe, with a concentration of 250 mg per 5 mL (50 mg per mL). It is meant for intramuscular use only and should be protected from light. The medication is manufactured in India for Eugia US LLC, located in E. Windsor, NJ 08520. There is also a code provided: TS/DRUGS/.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - Peel off Patient Record Label - fulvestrant fig16

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - Peel off Patient Record Label - fulvestrant fig16

This is a description of a medication called Fulvestrant Injection. It is available in a carton containing two single-dose prefilled syringes, each containing 250 mg of the medication. The syringes need to be administered together to receive the full 500 mg dose. The medication is to be refrigerated at 2 to 8 degrees Celsius and should be protected from light by storing it in the original carton until the time of use. The injection is to be administered intramuscularly, following local guidelines for performing large volume intramuscular injections. The package also contains two SafetyGlide™ shielding intramuscular injection needles. The injection should be administered into the buttock area slowly over 1 to 2 minutes. After administration, the lever arm on the syringe's needle should be activated to deploy the needle shielding. The empty syringe should be discarded in an approved sharps collector.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - Peel off Patient Record Label - fulvestrant fig17

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - Peel off Patient Record Label - fulvestrant fig17

fulvestrant figure2 - fulvestrant fig2

fulvestrant figure2 - fulvestrant fig2

fulvestrant figure3 - fulvestrant fig3

fulvestrant figure3 - fulvestrant fig3

fulvestrant figure4 - fulvestrant fig4

fulvestrant figure4 - fulvestrant fig4

fulvestrant figure5 - fulvestrant fig5

fulvestrant figure5 - fulvestrant fig5

fulvestrant figure6 - fulvestrant fig6

fulvestrant figure6 - fulvestrant fig6

fulvestrant figure7 - fulvestrant fig7

fulvestrant figure7 - fulvestrant fig7

fulvestrant figure8 - fulvestrant fig8

fulvestrant figure8 - fulvestrant fig8

fulvestrant figure9 - fulvestrant fig9

fulvestrant figure9 - fulvestrant fig9

fulvestrant structure - fulvestrant str

fulvestrant structure - fulvestrant str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.